Lineage Cell Therapeutics Inc
$ 1.10
-2.65%
07 Aug - close price
- Market Cap 278,198,000 USD
- Current Price $ 1.10
- High / Low $ 1.14 / 1.08
- Stock P/E N/A
- Book Value 0.18
- EPS -0.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.98 %
- 52 Week High 2.09
- 52 Week Low 0.97
About
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the United States and internationally. The company is headquartered in Carlsbad, California.
Analyst Target Price
$5.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-12 | 2026-03-05 | 2025-11-06 | 2025-08-12 | 2025-05-13 | 2025-03-10 | 2024-11-14 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 |
| Reported EPS | -0.03 | -0.0273 | 0.0035 | -0.13 | -0.13 | -0.02 | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 |
| Estimated EPS | -0.03 | -0.02 | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 | -0.04 | -0.03 |
| Surprise | 0 | -0.0073 | 0.0435 | -0.1 | -0.1 | 0.01 | 0.02 | 0.01 | 0.01 | 0 | 0.01 | -0.01 |
| Surprise Percentage | 0% | -36.5% | 108.75% | -333.3333% | -333.3333% | 33.3333% | 66.6667% | 33.3333% | 25% | 0% | 25% | -33.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.3125 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LCTX
2026-08-07 17:09:49
This article provides an earnings forecast for Lineage Cell Therapeutics Inc (LCTX), detailing its current earnings forecast score, average price target of $3.00, and analyst ratings. Based on 7 analysts, most recommend a "Buy" for the stock, with an upside potential of over 391%. The report also includes expected revenue and EPS for upcoming quarters.
2026-08-07 17:09:49
This article provides the transcript of Lineage Cell Therapeutics, Inc.'s Second Quarter 2026 Earnings Call, which took place on August 6, 2026. The content includes a message from the operator and indicates that an audio webcast is available. Full access to the transcript and other MarketScreener features requires a subscription.
2026-08-07 03:41:00
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced its Q2 2026 financial results, highlighting positive 3-year clinical data for OpRegen and progress with its COR1 corneal endothelial disease cell therapy program. The company reported a net income of $1.5 million for Q2 2026, a significant improvement from a net loss in the prior year, and expects its cash and marketable securities of $50.8 million to fund operations into Q3 2028. Lineage also provided updates on its other programs, including OPC1 for spinal cord injury and ReSonance for hearing loss, underscoring its balanced strategy of advancing its pipeline while supporting collaborations.
2026-08-06 22:52:00
Lineage Cell Therapeutics reported a narrow net income of $1.5 million for Q2 2026, a significant improvement from a $30.5 million loss a year prior, primarily due to a non-cash gain from warrant liability remeasurement, despite a 60.7% decline in revenue. The company extended its cash runway into Q3 2028 and is advancing its "Lineage 3.0" strategy to develop new cell therapy programs, including COR1 for corneal disease and ILT1 for diabetes, while awaiting progress on its lead OpRegen program with Roche. Management emphasized its AlloSCOPE manufacturing platform as a key differentiator for scalable, cost-effective cell production.
2026-08-03 17:14:07
This article highlights three penny stocks—Lineage Cell Therapeutics (LCTX), Yatsen Holding (YSG), and CreateAI Holdings (TSPH)—that possess market caps over $40 million and strong balance sheets. Despite some being unprofitable, these companies are noted for their financial resilience, including low or no debt, and potential for growth within their respective sectors like biotechnology, beauty products, and artificial intelligence. The piece emphasizes that these stocks offer compelling opportunities with less risk due to their sound financial health.
2026-08-01 06:10:49
Lineage Cell Therapeutics, Inc. (LCTX) generated $14.56 million USD in revenue last year, primarily from its Therapeutic Products segment. This marks an increase from $9.50 million USD in the previous year. The United States was the largest contributor to the company's revenue.
